Emyria teams with CRO PsychoGenics for MDMA-like Drug Development
By Joseph Keenan · Sep 21, 2022 · Fierce Biotech Australian biotech Emyria and U.S.-based CRO PsychoGenics have agreed to a collaborate on...
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP)
PARAMUS, N.J., November 6, 2019 – PGI Holding Corporation (PsychoGenics) announced that it has been awarded an Indefinite Delivery Indefinite...
PsychoGenics Launches Updated Corporate Identity and Brand
PsychoGenics, Inc. (“PsychoGenics” or the “Company”), the leading contract research organization (CRO) specializing in the central nervous system (CNS) focused preclinical and translational drug discovery services, is proud to unveil its refreshed corporate identity and brand.
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods.
Houghten, R. A.; Pinilla, C.; Giulianotti, M. A.; Appel, J. R.; Dooley, C. T.; Nefzi, A.; Ostresh, J. M.; Yu,...
In Vivo AI Platforms
PsychoGenics’ Cube Technologies: RevolutionizingNeuropsychiatric Drug Discovery CNS disorders impact hundreds of millions of patients who not only suffer from severely...
Immunohistochemistry (IHC) & Histology Services
PsychoGenics’ immunohistochemistry (IHC) and histology services offer exceptional data quality, enabling the exploration of standard and novel biomarkers. Our high-throughput...
PhenoCube® In Vivo AI Platform for Disease Model Phenotyping
Comprehensive Phenotypic Assessment of Disease Models PhenoCube® is an innovative platform where mice are observed continuously, day and night, allowing...
Standardized Locomotor and Sensory behavior changes in a graded contusive spinal cord injury model
Johana Bastidas1, Megan R. Detloff2, Linda Jones3, Marco Baptista3,Karim Fouad4, Taleen Hanania1. 1 Psychogenics, Paramus, New Jersey, US 2Department of...
Characterization of the Ube3a Mouse Model of Angelman Syndrome
Angelman Syndrome (AS) is a rare genetic neurodevelopmental disorder characterized, in part, by developmental delays, movement impairments, and difficulties with communication and language, the effects of which impact children and adults living with AS along with their caregivers. AS is most frequently caused by deletion or mutation of the Ube3a gene on the maternal allele. PsychoGenics has characterized the Ube3a mouse model of AS in both neonatal and adult mice.
Receptor Occupancy Services
At PsychoGenics, we specialize in measuring compound-target engagement through in vivo and ex vivo receptor occupancy (RO) services. By utilizing...